🚨🚨🚨
Rectal Cancer Tweetorial!!

Rectal cancer is a highly heterogeneous disease with rapid evolution in practice.

Let's review current data to generate a pragmatic, patient-centric, approach to management!
#GI24 #GIonc #RadOnc

Thank you @ASCO for the opportunity!🙏🏽

1/

✅Pre-operative RT reduces the risk of pelvic recurrence for patients with rectal cancer.

But some patients will suffer from acute and long term toxicity (bladder, bowel, sexual, endocrine dysfunction)

❓How can we tailor therapy to balance QoL & cancer control?
2/

🔥🔥🔥 Hey #GIonc #Radonc friends- rectal cancer management is evolving rapidly. Let’s run through a case-based review of rectal cancer!!!
#ASTRO23

55F
cT3aN0M0 rectal adenocarcinoma, pMMR
11 cm from the anal verge
No compromise of the mesorectal fascia or evidence of extramural venous invasion
Patient is amenable to low anterior resection

What would you recommend for management?

Hey #GIOnc #Radonc friends! Let’s talk definitive CRT for locally advanced esophagus cancer! Looks like we now have at least 5 RCTs exploring dose escalation… and the standard remains 50 Gy! Let’s review!! 🧵🧵🧵1/ RTOG 8501 established the standard care of 50.4 Gy + concurrent chemotherapy for patients with inoperable, locally advanced esophagus cancer
Nearly 90% were SCC.
🔵Long-term disease control/survival was achieved in approximately 25% of patients. 0% with RT alone!!! 2/

The Alliance A021501 trial has landed!
First- I’d like to congratulate the authors for conducting this study. Fantastic trial concept, and the rigorous review of eligibility and SBRT QA was exceptional
So much to unpack... Let’s dive in!
🧵🧵🧵
pubmed.ncbi.nlm.nih.gov/35834226/
1/ PDAC is a devastating dz. Most notable improvements over the past decades have been related to systemic therapy. Despite curative intent surgery, pts are at high risk of both locoregional and distant disease progression.

https://twitter.com/KrishanJethwa/status/1537512956925198336

2/